2022. Development of Nanocrystal Formulations With Improved Dissolution And Bioavailability for BCS Classs-II Drug- Quitapine. Journal of Pharmaceutical Negative Results. (Aug. 2022), 5113–5120. DOI:https://doi.org/10.47750/pnr.2022.13.S08.670.